Background/aims: Acute rejection is still a major problem after liver transplantation. Ursodeoxycholic acid has beneficial effects in cholestasis by reducing the expression of major histocompatibility complex antigens.
Methods: We have performed a double-blind randomised study comparing ursodeoxycholic acid with placebo for the prevention of acute cellular rejection after liver transplantation. Twenty-six patients received ursodeoxycholic acid 600 mg per day and 24 patients received placebo for 2 months.
Results: Neither rejection incidence nor rejection severity was significantly different in the two groups (p > 0.90).
Conclusions: We conclude that adjuvant ursodeoxycholic acid administration does not prevent rejection after liver transplantation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0168-8278(95)80324-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exploration of the Mechanism of Tanre Qing Injection in Treating Acute Respiratory Distress Syndrome through Network Pharmacology, Molecular Docking, and Animal Experiments.
Comb Chem High Throughput Screen
January 2025
Department of Pharmacy, Taicang TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Jiangsu, China.
Objective: This study aimed to explore the active components and potential mechanism of Tanre Qing Injection (TRQI) in the treatment of Acute Respiratory Distress Syndrome (ARDS) using network pharmacology, molecular docking, and animal experiments.
Methods: The targets of active ingredients were identified using the TCMSP and Swiss Target Prediction databases. The targets associated with ARDS were obtained from the GeneCards database, Mala card database, and Open Targets Platform.
Management of primary sclerosing cholangitis: Current state-of-the-art.
Hepatol Commun
December 2024
Division of Gastroenterology and Hepatology, Department of Medicine, The Autoimmune and Rare Liver Disease Programme, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada.
Article Synopsis
- Primary sclerosing cholangitis is a chronic liver condition associated with inflammation and fibrosis of bile ducts, often linked to inflammatory bowel disease and increases the risk of cancer.
- Current treatments mainly offer supportive care, as there are no effective medical therapies available and liver transplantation can prolong life but does not cure the disease.
- Research is ongoing into new therapies aimed at slowing disease progression and alleviating symptoms, with improved trial designs focused on selecting appropriate patients and using better outcome measures to assess treatment effectiveness.
Cholelithiasis in Infants: Risk Factors, Management, and the Role of Ursodeoxycholic Acid.
Children (Basel)
December 2024
Department of Pediatrics, Division of Pediatric Gastroenterology, University of Health Sciences Dr. Behçet Uz Children's Hospital, Izmir 35210, Turkey.
Background: Cholelithiasis is a rare disease in infants, and there is limited data on its risk factors and management.
Objectives: To evaluate the risk factors, management, and response to medical treatment of cholelithiasis in infants.
Methods: Infants diagnosed with cholelithiasis by ultrasound between 2018 and 2023 were retrospectively analyzed.
The effect of fecal bile acids on the incidence and risk-stratification of colorectal cancer: an updated systematic review and meta-analysis.
Sci Rep
January 2025
Department of Colorectal Surgery, Ningbo Medical Center Lihuili Hospital, Ningbo, 315000, China.
Recent studies suggest the role of gut microbes in bile acid metabolism in the development and progression of colorectal cancer. However, the surveys of the association between fecal bile acid concentrations and colorectal cancer (CRC) have been inconsistent. We searched online to identify relevant cross-sectional and case-control studies published online in the major English language databases (Medline, Embase, Web of Science, AMED, and CINAHL) up to January 1, 2024.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!